Sign in
TerminatedPhase 2

Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock.

Key facts

Who runs it
Centre Hospitalier de Bethune
Where
France14 sites in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 2
People taking part
65 people enrolled
Started
27 Dec 2023
Ended
30 Sept 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Vitamin C (Laroscorbine) + Vitamin B1 (Bevitine)
  • standard treatment
Record updated
27 October 2026
Why it stopped
following new data on vitamin C and at the request of the ANSM

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • patients still comatose (Glasgow coma scale < 8) after an OHCA of presumed cardiac origin with ROSC < 60 min
  • and treated with a norepinephrin or an epinephrin continuous infusion during at least 30 min before randomization to maintain mean arterial pressure (MAP) ≥ 65 mmHg

Who cannot take part

  • and treated with a norepinephrin or an epinephrin continuous infusion ≥ 0.2µg/kg/h, within 4 hours after OHCA, during at least 30 min/h to maintain mean arterial pressure (MAP) ≥ 65 mmHg
  • patients already treated with vit-C; known vit-C deficit
  • patients still comatose (Glasgow coma scale < 8) after an OHCA of presumed cardiac origin with ROSC < 60 min
  • OHCA from evident extracardiac cause (trauma, bleeding, poisoning, etc.)
  • history of urolithiasis, oxalate nephropathy or hemochromatosis
  • pre-existent severe chronic kidney disease (glomerular filtration rate < 30ml/min)
  • glucose-6-phosphate deshydrogenase deficiency; nephrolithiasis, hyperoxalyurie
  • minor or pregnant women
  • interval between RACS and randomization > 6 hours
  • extracorporeal circulatory assistance requirement in the first 4 hours after OHCA
  • inclusion in another study
  • treatment limitationsor moribound
  • Patient with derpived freedom or with legal protective measures
  • Patient not covered by French national health insurance

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Among patients admitted after an out-of-hospital cardiac arrest (OHCA) in intensive care unit (ICU), almost two thirds of patients will develop in the first hours a post-cardiac arrest (CA) shock. This post-CA shock, combines cardiac and hemodynamic failure, generally resulting in multi-organ failure and early death in up to 35% of patients. Experimental data suggest that intravenous ascorbic acid (vitamin C) may attenuate inflammation and vascular injury related to sepsis or surgery. Preclinical and clinical studies also provide safety data of high dose intravenous vitamin C (> 200mg/kg/day) with no significant adverse event reported and favorable impact on outcome. Experimental data also suggest beneficial effect of vitamin C in post-CA management with improvement of shock and multi-organ failure with potential benefit on neuroprotection and outcome.

Read full original descriptionShow less

The study is a phase II multicenter prospective controlled open-label trial randomized in two parallel groups :

* Expérimental group: Standard of care care for post-CA shock + Vitamin C (Vit-C) 200mg/kg/d IV (started as early as possible, no later than 1 h after randomization + thiamin (Vit B1) 200mg every 12 h during 3 days. * Control group: Standard of care care for post CA shock according international guidelines.

Patient number to be enrolled : 234, Study duration :24 months and 28 days, Inclusion duration : 24 months, Patient participation : duration : 28 days

The 2 groups in the trial

  • Control groupExisting treatment, for comparison

    \- Control group (standard treatment): post-cardiac arrest care will be provided, including temperature control, according to current international guidelines and local procedures. Standard IV vit-C supplementation will be allowed for dosages up to 1000 mg a day from day 4 after randomization, as well as thiamin supplementation.

    Treatment: standard treatment

  • Experimental groupTreatment being tested

    \- Experimental group (IV high-dose vit-C): in addition of standard post-CA as the control group, patients will receive an IV high-dose vit-C 50mg/kg infusion every 6 hours, started within the hour after randomization, for 3 days. In addition, all patients will receive intravenous thiamine 200 mg twice a day for 3 days to limit the oxalate production.

    Treatment: Vitamin C (Laroscorbine) + Vitamin B1 (Bevitine)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock: a Multicenter, Randomized Controled Trial.
Publications
Record updated
27 October 2026